Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphangioleiomyomatosis × Celecoxib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 29 Breast Neoplasms 23 Lung Neoplasms 22 Carcinoma, Non-Small-Cell Lung 22 Colonic Neoplasms 15 Head and Neck Neoplasms 13 Rectal Neoplasms 12 Prostatic Neoplasms 11 Sarcoma 8 Neoplasm Metastasis 8 Pancreatic Neoplasms 7 Esophageal Neoplasms 7 Adenomatous Polyposis Coli 7 Neoplasms 6 Mouth Neoplasms 6 Glioblastoma 6 Precancerous Conditions 5 Ovarian Neoplasms 5 Melanoma 5 Central Nervous System Neoplasms 5 Unspecified Adult Solid Tumor, Protocol Specific 4 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Neuroblastoma 4 Gliosarcoma 4 Carcinoma 4 Urinary Bladder Neoplasms 3 Oropharyngeal Neoplasms 3 Multiple Myeloma 3

Interventions

Sirolimus 10 Everolimus 4 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 carbon-11 acetate 1 Valproic Acid 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Respiratory Function Tests 1 Phlebotomy 1 Octreotide 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Genetic Testing 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02484664 2022-01-20

COLA

Brigham and Women's Hospital

Phase 2 Completed

12 enrolled 11 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡